期刊文献+

达那唑抑制SKM-1细胞活性并促使细胞凋亡

Danazol inhibits cell viability and promotes apoptosis in SKM-1 cells
下载PDF
导出
摘要 目的研究达那唑对骨髓增生异常综合征(myelodysplastic syndrome,MDS)细胞系SKM-1细胞活性、凋亡以及肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)信号通路的影响。方法用0、10、20和40μmol/L达那唑处理SKM-1细胞后,通过MTT法检测细胞活性,通过流式细胞实验分析细胞周期和细胞凋亡,通过TUNEL染色法检测TUNEL阳性细胞比例,通过Western blot检测TRAIL介导的细胞凋亡相关蛋白的表达情况。结果达那唑可呈浓度依赖性地抑制SKM-1细胞活力,降低S期中细胞比率,提高细胞凋亡比率。Western blot结果显示达那唑可使Cleaved caspase-8和Cleaved PARP1水平升高。结论达那唑可抑制SKM-1细胞活性并促进其凋亡,其机制可能与激活TRAIL信号通路相关。 Objective To study the effect of danazol on the cell viability and apoptosis of SKM-1 cell line of myelodysplastic syndrome(MDS)and its impact on TNF related apoptosis inducing ligand(TRAIL)signal pathway.Methods SKM-1 cells were treated with 0,10,20 and 40μmol/L danazol,then the cell viability was detected by MTT assay,the cell cycle and apoptosis were analyzed by flow cytometry,the proportion of TUNEL positive cells was detected by TUNEL staining,and the expression of TRAIL-mediated apoptosis related proteins were detected by Western blot.Results Danazol inhibited cell viability,decreased the ratio of cells in S phase,and increased the apoptotic rate of SKM-1 cells in a concentration dependent manner.Western blot showed that danazol increased Cleaved caspase-8 and Cleaved PARP1 expression.Conclusion Danazole can inhibit the cell viability and promote the apoptosis of SKM-1 cells,and the mechanism may be related to the activation of TRAIL signaling pathway.
作者 张永晓 刘珊 陈园园 王冬梅 Zhang Yongxiao;Liu Shan;Chen Yuanyuan;Wang Dongmei(Department of Hematopathology,Harraison International Peace Hospital,Hengshui 053000,China)
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2021年第1期1-6,共6页 Chinese Journal of Histochemistry and Cytochemistry
基金 河北省卫计委医学科学研究重点课题计划项目(20181567)。
关键词 骨髓增生异常综合征 达那唑 凋亡 TRAIL Myelodysplastic syndrome danazol apoptosis TRAIL
  • 相关文献

参考文献3

二级参考文献22

  • 1胡晓梅,唐旭东,麻柔,羊裔明.骨髓增生异常综合征发病机制的研究进展[J].国际输血及血液学杂志,2006,29(2):132-136. 被引量:15
  • 2林凤茹,王艳.骨髓增生异常综合征临床研究进展[J].白血病.淋巴瘤,2006,15(2):158-160. 被引量:6
  • 3胡晓静,丛雅琴.骨髓增生异常综合征线粒体异常的研究进展[J].国际输血及血液学杂志,2006,29(3):213-215. 被引量:3
  • 4周永明,田胜利,周韶虹,薛志忠,何玮,罗梅宏,胡明辉,许毅.骨髓增生异常综合征患者JAK2和STAT5基因表达的变化[J].临床血液学杂志,2007,20(2):70-72. 被引量:2
  • 5Ha Thanh Nishino, Chung-Che Chang. Myelodysplastic Syndromes Chnicopathologic Features, Pathobiology, and Molecular Pathogenesis [ J ]. Review Article, 2005, 129 : 1299-1310.
  • 6Solomon PR, Munirajan AK, Andiappan Rathinavel GS, et al. Promoter hypermethylation analysis in myelodysplasfie syndromes: Diagnostic & prognostic implication [J]. Indian J Med Res, 2008, 127: 52-57.
  • 7Silvia Buonamici, Donglan Li, Yiqing Chi, et al. EVIl induces myelodysplastic syndrome in mice [ J ]. The Journal of Clinical Investigation, 2004, 114(5): 713-719.
  • 8Ulrike Bacher, Torsten Haferlach, Wolfgang Kern, et al. A comparative study of molecular mutations in 381 patients with myelodysplastie syndrome and in 4130 patients with acute myeloid leukemia [ J ]. The hematology jouma, 2007, 92 (06) : 744-752.
  • 9Akira Miyazato, Shuichi Ueno, Ken Ohmine, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction [J]. Blood, 2001, 98: 422-427.
  • 10Hisamaru Hirai. Molecular Mechanisms of Myelodysplastic Syndrome [J]. Jpn J Clin Oncol, 2003, 33(4) : 153-160.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部